【24h】

Lethal cerebral hemorrhage after ticagrelor intoxication: a specific antidote is urgently needed

机译:TicagreloLor中毒后的致命脑出血:迫切需要特定的解毒剂

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Ticagrelor is a direct and reversible competitive antagonist of the P2Y12 receptor and inhibits platelet activation. Although adverse bleeding is common, fatal intoxication has never been documented. Case description: A 47-year-old man died from a severe cerebral hemorrhage secondary to a fall and cranial trauma 4 d after the massive intake of ticagrelor. Iterative platelet transfusions did not improve his condition. Toxicological analyses by liquid chromatography tandem mass spectrometry (LC-MS/MS) revealed high plasma concentrations of ticagrelor (3343 mu g/L) and its active metabolite AR-C124910XX (656 mu g/L) 10 h after intake. The approximate ingested dose was extrapolated to 1677 mg. Assessment of ADP-induced platelet aggregation and platelet Vasodilator Stimulated Phosphoprotein phosphorylation (VASP), 2 and 3 d after admission, respectively, showed the persistence of platelet inhibition. Discussion: To the best of our knowledge, no prior fatal cases have been reported and documented with both ticagrelor and AR-C124910XX concentrations. Our findings highlight the need for a specific antidote to manage such complications resulting from ticagrelor overdose.
机译:背景:TiCagrelor是P2Y12受体的直接和可逆的竞争性拮抗剂,并抑制血小板活化。虽然不利出血是常见的,但从未记录过致命的中毒。案例描述:一名47岁的男子从突然摄入后的秋季和颅骨创伤4d中的严重脑出血中死亡。迭代血小板输血并未改善他的病情。通过液相色谱串联质谱(LC-MS / MS)显示毒理学分析(LC-MS / MS)揭示了在摄入后10小时的高血浆浓度(3343μg/ L)及其活性代谢物Ar-C124910xx(656μg/ l)。将近似摄入剂量推断为1677mg。分别评估ADP诱导的血小板聚集和血小板血管扩张剂刺激磷蛋白磷酸化(VASP),2和3d分别在入院后,表现出血小板抑制的持续性。讨论:据我们所知,没有报告致命病例,并记录了Ticagreles和Ar-C124910xx浓度。我们的研究结果强调了特定的解毒剂来管理由TicagreloLor过量产生的这种并发症。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号